Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Tasadenoturev active in DIPG1248
From little subclones grow mighty oaks1205
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC853
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC838
Sacituzumab govitecan plus pembrolizumab improves outcomes775
Hodgkin lymphoma: great progress with room for improvement686
Ecological management of the microbiota in patients with cancer680
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma581
A new standard of care for advanced-stage urothelial carcinoma556
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes518
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines517
Novel ICI–TKI combination improves HCC outcomes497
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles482
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown476
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials475
Current understanding and management of CAR T cell-associated toxicities462
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime398
Gut microbiota in colorectal cancer development and therapy361
Ponatinib superior to imatinib in Ph+ ALL344
Mortality is similar with active monitoring343
From ESMO 2022330
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC327
Sacituzumab tirumotecan improves OS in mTNBC321
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials321
Belzutifan as a new option in pheochromocytomas and paragangliomas318
Emerging trends in the global burden of colorectal cancer315
Understanding and overcoming multidrug resistance in cancer313
Humanized mouse models for immuno-oncology research311
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence309
Minimal residual disease as a target for liquid biopsy in patients with solid tumours303
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC299
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer279
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma271
Craniospinal irradiation improves leptomeningeal metastasis control257
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours254
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs251
Vebreltinib effective in MET-amplified NSCLC242
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease235
Unresectable stage III non-small-cell lung cancer: state of the art and challenges220
Improving outcomes in patients with oesophageal cancer213
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship207
MicroRNAs in oncology: a translational perspective in the era of AI204
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response197
Spatial landscapes of cancers: insights and opportunities195
Biomarkers for immunotherapy of hepatocellular carcinoma195
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests187
Approvals in 2022: overall survival, dose optimization, new approvals and beyond183
SHINE a light: frontline ibrutinib for MCL168
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC163
Women with clinically node negative breast cancer can safely avoid axillary surgery162
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’159
Domvanalimab plus zimberelimab shows promise in upper-tract cancers158
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma144
Prospective comparisons support the use of navigational bronchoscopy140
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC132
Synergistic integration of regional and systemic therapies in uveal melanoma131
From ESMO 2023: advances in lung cancer131
DREAMseq of therapy for BRAF-mutant melanoma131
Targeting chromosomal instability in patients with cancer130
Mitigating acute chemotherapy-associated adverse events in patients with cancer128
Circulating tumour DNA — looking beyond the blood127
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM120
Long-term outcomes following CAR T cell therapy: what we know so far120
Multiomics STEP up in correlative analysis of response to CAR T cells116
From the ESMO Congress 2023113
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas111
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC111
Sentinel lymph node biopsy improves surgical management of cervical cancer110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL105
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma103
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress102
Author Correction: Innovative approaches for lung cancer screening and interception101
Claudin 18.2 as a novel therapeutic target100
Lung cancer in patients who have never smoked — an emerging disease97
Newly approved cancer drugs in China — innovation and clinical benefit95
Clinical implications of T cell exhaustion for cancer immunotherapy95
Enhancing immunotherapy with tumour-responsive nanomaterials95
Targeted biopsy reduces detection of clinically insignificant cancer94
T-DXd effective as second-line therapy in G/GEJ cancers93
Second-line tarlatamab improves OS in SCLC92
Less-frequent surveillance is noninferior to annual mammography90
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy88
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine85
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology83
0.21360516548157